Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in
patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Chonbuk National University Hospital Chungnam National University Gachon University Gil Medical Center Gangnam Severance Hospital Gyeongsang National University Hospital Hallym University Medical Center Inje University Korea Cancer Center Hospital Seoul National University Boramae Hospital Seoul National University Bundang Hospital The Catholic University of Korea Wonju Severance Christian Hospital